Morgan Stanley lowered the firm’s price target on Acadia Pharmaceuticals to $28 from $30 and keeps an Overweight rating on the shares. The firm lowered Daybue sales estimates for Q2 and 2024 and raised Daybue pricing assumptions, leading to its trimmed target, the analyst tells investors in a Biotechnology group preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD: